ALK-Abello AS SWOT Analysis and Company Tech Intelligence Report 2018

Report Name: ALK-Abello AS  Profile – Overview, History, SWOT Analysis, Products/Services, Facts, Financials, Key Executives, Competitors, Tech Intelligence, IT Outsourcing, IT Management, Recent Developments and Strategy Evaluation

ALK-Abello AS Report – Publisher: Research Cosmos

Price Scheme of the Report:

Single User License – USD 150

Team License – USD 175

Corporate License – USD 250

ALK-Abello AS – Business Description:

ALK-Abello AS is a global research-driven pharmaceutical company that focuses on prevention, diagnosis and treatment of allergies. The group has its operations in Europe, North America and other parts of the world.

The group functions in one operating segment: allergy treatment.

Allergy immunotherapy (AIT) is a treatment which both reduces allergic symptoms and treats the underlying cause of a specific allergy. AIT is administered in three different ways: SCIT (subcutaneous injections), SLIT-drops (sublingual drops) or SLIT-tablets (sublingual tablets).

In the SCIT and SLIT-drops product group, ALK-Abello manufactures and markets SCIT (also known as subcutaneous allergy immunotherapy injections) against many types of allergy, including respiratory allergy for house dust mite, grass pollen, tree pollen, ragweed pollen and Japanese cedar pollen. The company also provides venom immunotherapy, a life-saving cure for patients suffering from bee and wasp allergies. Alutard SQ is one of ALK-Abello’s leading products for subcutaneous allergy immunotherapy. The group manufactures and markets SLIT drops (also known as sublingual allergy immunotherapy drops). SLITone, a droplet for daily administration through a single dose container, is used for most common allergies, such as pollens (grasses, trees and weeds), pets, and molds and mites.

The SLIT-tablets (sublingual allergy immunotherapy tablets) are fast dissolving tablets which dissolve under the tongue and can be administered by patients at home. The SLIT-tablets also include revenues from partnerships, product supply, reimbursements, milestones and royalties. Grazax is ALK-Abello’s SLIT tablet, used for grass pollen allergy. The group’s other tablet-based allergy vaccines include tablets against house dust mite, ragweed, cat and tree pollen allergy.

Other products and services product group of Alk-Abello includes diagnostic tests that can help identify specific allergies; adrenaline auto-injector pen, Jext, for emergency interventions in potentially life-threatening cases of anaphylaxis. Under its allergy diagnostics services, the group provides diagnosis for optimal allergy treatment for a specific treatment of the actual cause of the patient’s allergy. As a supplement to the therapeutic products, ALK-Abello manufactures allergen extracts for allergy testing, such as skin-prick tests. Other products and services offered by the group also includes allergy emergency treatment services, under which ALK-Abello is a partner in the management of anaphylaxis (a severe allergic reaction to food allergy or untreated allergy to insect venom), and provides education and relevant information for patients and carers.

Scope of the Report:

About the Company: Historical Details, Current Ownership Structure and basic overview of Balfour Beatty plcin terms of revenue, net income, and operating income.

Financials: Details about Balfour Beatty plclisting status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.

Products/Services: Listing of the company’s entire portfolio along with the description of individual products/services providing a clear picture of their target audience.

Company SWOT Analysis: Outlines Atea ASA.’s strengths, weaknesses, and opportunities and threats facing the company.

Recent Developments: Showcases Atea ASA.’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.

Strategic Evaluation: This section provides an overview of Atea ASA.’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.

Technology Landscape: Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken by the company at present along with outlook.

Key Questions Answered

What domain does Balfour Beatty plcoperate and what are key points about it?

What is the product/service portfolio of Atea ASA.?

How has Balfour Beatty plcperformed financially from 2013?

How does Balfour Beatty plcrank among its peers in terms of revenue and market share?

What are Balfour Beatty plcstrengths and weaknesses and what opportunities and threats do it face?

What are Atea ASA.’s main growth strategies and how successful has the company been at implementing them?

What is the in-house technical capability of Atea ASA.? Where does it procure/outsource it?

Reasons to buy

Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own

Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at a very competitive cost

12 hour delivery time fulfilling your urgent requests as per your requirement

On-demand customization options that can completely cater to your needs by focusing the report on given specifics

For More Information, Get Sample of the report:Request Sample

Got Some Questions? Inquire Here:Inquire Before Buying

Get This Report:Purchase Now

For More Details, Contact Provider Directly:

Kevin Stewart
Sales Manager
Research Cosmos
kevin@researchcosmos.com
+1 888 709 8757

Be the first to comment

Leave a Reply